Abstact

Cervical cancer remains a leading cause of cancer-related mortality among women globally. Current therapeutic approaches primarily target single molecular pathways, often resulting in limited efficacy, drug resistance, and significant side effects. In this study, we developed novel multi-compound therapeutic platform for cervical cancer treatment, demonstrating superior efficacy compared to conventional single-target approaches. We employed computational network pharmacology analysis to identify eight bioactive compounds targeting key cervical cancer pathways including apoptosis, cell cycle regulation, angiogenesis, and metastasis. Mechanistic studies included assessment of selectivity, apoptosis, cell cycle, autophagy, pathway analysis, and gene expression profiling. Interestingly, the multi-compound formulation demonstrated significantly superior cytotoxic activity compared to conventional chemotherapeutic agents with enhanced selectivity for cancer cells over normal cells. The formulation induced intrinsic mitochondrial apoptosis via p53 and ER-stress, arrested cell cycle at G2/M checkpoint and inhibited autophagy. The network analysis identified 564 key protein targets across 178 pathways related to cervical cancer. This multi-compound approach addresses critical limitations of current cervical cancer treatments by targeting multiple pathways simultaneously to reduce resistance potential. The formulation utilizes established compounds with known safety profiles which facilitates regulatory approval pathways. In conclusion, this therapeutic platform represents a significant advancement in cervical cancer treatment strategy with demonstrated synergistic efficacy, enhanced selectivity, and multi-pathway mechanism of action that facilitates its clinical translation. Current efforts focus on formulation optimization, standardization protocols, and IND-enabling studies to advance toward Phase I clinical trials.